Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms.

Nucleoside analogues such as acyclovir and ganciclovir have been the mainstay of therapy for alphaherpesviruses (herpes simplex virus (HSV) and varicella-zoster virus (VZV)) and cytomegalovirus (CMV) infections, respectively. Drug-resistant herpesviruses are found relatively frequently in the clinic, almost exclusively among severely immunocompromised patients receiving prolonged antiviral therapy. For instance, close to 10% of patients with AIDS receiving intravenous ganciclovir for 3 months excrete a drug-resistant CMV isolate in their blood or urine and this percentage increases with cumulative drug exposure. Many studies have reported that at least some of the drug-resistant herpesviruses retain their pathogenicity and can be associated with progressive or relapsing disease. Viral mutations conferring resistance to nucleoside analogues have been found in either the drug activating/phosphorylating genes (HSV or VZV thymidine kinase, CMV UL97 kinase) and/or in conserved regions of the viral DNA polymerase. Currently available second line agents for the treatment of herpesvirus infections--the pyrophosphate analogue foscarnet and the acyclic nucleoside phosphonate derivative cidofovir--also inhibit the viral DNA polymerase but are not dependent on prior viral-specific activation. Hence, viral DNA polymerase mutations may lead to a variety of drug resistance patterns which are not totally predictable at the moment due to insufficient information on specific drug binding sites on the polymerase. Although some CMV and HSV DNA polymerase mutants have been found to replicate less efficiently in cell cultures, further research is needed to correlate viral fitness and clinical outcome.

[1]  F. Baldanti,et al.  Double resistance to ganciclovir and foscarnet of four human cytomegalovirus strains recovered from AIDS patients , 1995, Journal of medical virology.

[2]  F. Baldanti,et al.  A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate , 1995, Journal of virology.

[3]  S. Kemmerly,et al.  Foscarnet-resistant herpes simplex virus infection in patients with AIDS. , 1994, The Journal of infectious diseases.

[4]  T. Tsurumi,et al.  A single-base change within the DNA polymerase locus of herpes simplex virus type 2 can confer resistance to aphidicolin , 1987, Journal of virology.

[5]  G. Boivin,et al.  Characterization of the DNA polymerase and thymidine kinase genesof herpes simplex virus isolates from AIDS patients in whom acyclovirand foscarnet therapy sequentially failed. , 1999, The Journal of infectious diseases.

[6]  G. Drusano,et al.  Susceptibilities of Human Cytomegalovirus Clinical Isolates to BAY38-4766, BAY43-9695, and Ganciclovir , 2001, Antimicrobial Agents and Chemotherapy.

[7]  B. Lina,et al.  Phenotypic and Genetic Characterization of Thymidine Kinase from Clinical Strains of Varicella-Zoster Virus Resistant to Acyclovir , 1999, Antimicrobial Agents and Chemotherapy.

[8]  H. Balfour,et al.  Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. , 1997, The Journal of infectious diseases.

[9]  E. Davie,et al.  Primary structure of the catalytic subunit of calf thymus DNA polymerase delta: sequence similarities with other DNA polymerases. , 1991, Biochemistry.

[10]  M. Bergeron,et al.  A case of ganciclovir‐resistant cytomegalovirus (CMV) retinitis in a patient with AIDS: longitudinal molecular analysis of the CMV viral load and viral mutations in blood compartments , 1997, AIDS.

[11]  M. Kurokawa,et al.  Characterization of the DNA polymerase gene of varicella-zoster viruses resistant to acyclovir. , 2001, The Journal of general virology.

[12]  C. Wilcox,et al.  Replication, latent infection, and reactivation in neuronal culture with a herpes simplex virus thymidine kinase-negative mutant. , 1992, Virology.

[13]  H. Agut,et al.  Acyclovir‐resistant Varicella‐Zoster virus: Phenotypic and genetic characterization , 1998, Journal of medical virology.

[14]  D. Persing,et al.  Role of Genotypic Analysis of the Thymidine Kinase Gene of Herpes Simplex Virus for Determination of Neurovirulence and Resistance to Acyclovir , 1999, Journal of Clinical Microbiology.

[15]  P. Pothier,et al.  Value of a ligase chain reaction assay for detection of ganciclovir resistance-related mutation 594 in UL97 gene of human cytomegalovirus. , 1997, Journal of virological methods.

[16]  T. Burnette,et al.  Acyclovir Is Phosphorylated by the Human Cytomegalovirus UL97 Protein , 1999, Antimicrobial Agents and Chemotherapy.

[17]  M. Blasco,et al.  A general structure for DNA-dependent DNA polymerases. , 1991, Gene.

[18]  D. Barry,et al.  Plaque autoradiography assay for the detection and quantitation of thymidine kinase-deficient and thymidine kinase-altered mutants of herpes simplex virus in clinical isolates , 1985, Antimicrobial Agents and Chemotherapy.

[19]  D. Coen,et al.  Identification of amino acids in herpes simplex virus DNA polymerase involved in substrate and drug recognition. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[20]  S. Chou,et al.  A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. , 2000, The Journal of infectious diseases.

[21]  G. Boivin,et al.  Highly Reliable Heterologous System for Evaluating Resistance of Clinical Herpes Simplex Virus Isolates to Nucleoside Analogues , 2001, Journal of Virology.

[22]  C. Crumpacker,et al.  Recurrence and Resistance Patterns of Herpes Simplex Virus following Cessation of ⩾6 Years of Chronic Suppression with Acyclovir , 1994 .

[23]  S. Chou,et al.  Detection of ganciclovir resistance mutations quantitation of cytomegalovirus (CMV) DNA in leukocytes of patients with fatal disseminated CMV disease. , 1996, The Journal of infectious diseases.

[24]  R. Tenser,et al.  Latency-associated transcript but not reactivatable virus is present in sensory ganglion neurons after inoculation of thymidine kinase-negative mutants of herpes simplex virus type 1 , 1989, Journal of virology.

[25]  D. Jabs,et al.  Cytomegalovirus retinitis and viral resistance. Prevalence of resistance at diagnosis, 1994. Cytomegalovirus Retinitis and Viral Resistance Study Group. , 1996, Archives of ophthalmology.

[26]  Coinfection of the immunocompromised but not the immunocompetent host by multiple human cytomegalovirus strains , 1998, Archives of Virology.

[27]  H. Otsuka,et al.  Nucleotide sequence changes in thymidine kinase gene of herpes simplex virus type 2 clones from an isolate of a patient treated with acyclovir , 1987, Antimicrobial Agents and Chemotherapy.

[28]  E. Clercq,et al.  Therapeutic potential of HPMPC as an antiviral drug , 1993 .

[29]  F. Baldanti,et al.  Monitoring of ganciclovir sensitivity of multiple human cytomegalovirus strains coinfecting blood of an AIDS patient by an immediate-early antigen plaque assay. , 1992, Antiviral research.

[30]  G. Raghu,et al.  High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. , 2002, The Journal of infectious diseases.

[31]  R. Narwa,et al.  Value of a new rapid non-radioactive sequencing method for analysis of the cytomegalovirus UL97 gene in ganciclovir-resistant strains. , 1995, Journal of virological methods.

[32]  M. Aymard,et al.  Herpes Simplex Virus Isolates from an Immunocompromised Patient who Failed to Respond to Acyclovir Treatment Express Thymidine Kinase with Altered Substrate Specificity , 1991 .

[33]  F. Baldanti,et al.  Four dually resistant human cytomegalovirus strains from AIDS patients: single mutations in UL97 and UL54 open reading frames are responsible for ganciclovir- and foscarnet-specific resistance, respectively. , 1995, Scandinavian journal of infectious diseases. Supplementum.

[34]  C. B. Hwang,et al.  An altered spectrum of herpes simplex virus mutations mediated by an antimutator DNA polymerase. , 1995, Gene.

[35]  S. Lemon,et al.  Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial. , 1988, JAMA.

[36]  P. Griffiths,et al.  Quantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapy , 1999, Journal of medical virology.

[37]  T. Hunter,et al.  The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. , 1988, Science.

[38]  F. Kühn,et al.  Herpes Simplex Virus Type 1 DNA Polymerase , 1996, The Journal of Biological Chemistry.

[39]  D. Wolf,et al.  Early emergence of ganciclovir-resistant human cytomegalovirus strains in children with primary combined immunodeficiency. , 1998, The Journal of infectious diseases.

[40]  P. Collins,et al.  Sensitivity monitoring of clinical isolates of herpes simplex virus to acyclovir , 1993, Journal of medical virology.

[41]  D. Mount,et al.  Sequence and mapping analyses of the herpes simplex virus DNA polymerase gene predict a C-terminal substrate binding domain. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[42]  D. Coen,et al.  Human Cytomegalovirus Mutant with Sequence-Dependent Resistance to the Phosphorothioate Oligonucleotide Fomivirsen (ISIS 2922) , 1998, Antimicrobial Agents and Chemotherapy.

[43]  L. Blanco,et al.  A conserved 3′→5′ exonuclease active site in prokaryotic and eukaryotic DNA polymerases , 1989, Cell.

[44]  J. Cherrington,et al.  A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. , 1998, Virology.

[45]  D. Schoenfeld,et al.  Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis , 2000, Transplant infectious disease : an official journal of the Transplantation Society.

[46]  H. Offret,et al.  Acyclovir-resistant bilateral keratitis associated with mutations in the HSV-1 thymidine kinase gene. , 2000, Experimental eye research.

[47]  T. Klingebiel,et al.  Comprehensive restriction analysis of the UL97 region allows early detection of ganciclovir-resistant human cytomegalovirus in an immunocompromised child. , 1999, The Journal of infectious diseases.

[48]  S. Mori,et al.  Genetic analysis of a ganciclovir-resistant human cytomegalovirus mutant. , 1998, Antiviral research.

[49]  E. De Clercq,et al.  Differential Susceptibility of Several Drug-Resistant Strains of Herpes Simplex Virus Type 2 to Various Antiviral Compounds , 1997 .

[50]  F. Tufaro,et al.  Allele replacement: an application that permits rapid manipulation of herpes simplex virus type 1 genomes , 1999, Gene Therapy.

[51]  J. Huraux,et al.  Single amino acid change in DNA polymerase is associated with foscarnet resistance in a varicella-zoster virus strain recovered from a patient with AIDS. , 1998, The Journal of infectious diseases.

[52]  C. Crumpacker,et al.  Interstrain Variation in the Human Cytomegalovirus DNA Polymerase Sequence and Its Effect on Genotypic Diagnosis of Antiviral Drug Resistance , 1999, Antimicrobial Agents and Chemotherapy.

[53]  D. Wolf,et al.  Emergence of Multiple Human Cytomegalovirus Ganciclovir-Resistant Mutants with Deletions and Substitutions within the UL97 Gene in a Patient with Severe Combined Immunodeficiency , 2001, Antimicrobial Agents and Chemotherapy.

[54]  S. Follansbee,et al.  Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. , 1990, The Journal of infectious diseases.

[55]  J. Huraux,et al.  Point mutations in the varicella‐zoster virus DNA polymerase gene confers resistance to foscarnet and slow growth phenotype , 1999, Journal of medical virology.

[56]  A. Erice,et al.  Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir , 1991 .

[57]  D. Coen,et al.  Polymerization activity of an alpha-like DNA polymerase requires a conserved 3'-5' exonuclease active site , 1991, Molecular and cellular biology.

[58]  S. Swetter,et al.  Chronic vulvar ulceration in an immunocompetent woman due to acyclovir-resistant, thymidine kinase-deficient herpes simplex virus. , 1998, The Journal of infectious diseases.

[59]  F. Baldanti,et al.  Mutations in the UL97 ORF of ganciclovir-resistant clinical cytomegalovirus isolates differentially affect GCV phosphorylation as determined in a recombinant vaccinia virus system. , 2002, Antiviral research.

[60]  K. Tyler,et al.  Progressive esophagitis from acyclovir-resistant herpes simplex. Clinical roles for DNA polymerase mutants and viral heterogeneity? , 1989, Annals of internal medicine.

[61]  N. Lurain,et al.  Molecular analysis of human cytomegalovirus strains from two lung transplant recipients with the same donor. , 1996, Transplantation.

[62]  P. Crosson,et al.  Antiviral susceptibilities of herpes simplex virus from immunocompetent subjects with recurrent herpes labialie: a UK-based survey. , 2000, The Journal of antimicrobial chemotherapy.

[63]  H. Einsele,et al.  European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT). , 1996, Bone marrow transplantation.

[64]  R. Miller,et al.  Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine. , 1978, The Journal of biological chemistry.

[65]  W. Freeman,et al.  High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. , 1997, The Journal of infectious diseases.

[66]  D. H. Watts,et al.  Antiviral agents. , 1992, Obstetrics and gynecology clinics of North America.

[67]  E. De Clercq,et al.  A new topical treatment for resistant herpes simplex infections. , 1993, The New England journal of medicine.

[68]  M. Chee,et al.  Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir , 1992, Nature.

[69]  J. Cherrington,et al.  Susceptibility of Human Cytomegalovirus to Cidofovir Is Unchanged after Limited In Vivo Exposure to Various Clinical Regimens of Drug , 1996 .

[70]  P. Griffiths,et al.  Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[71]  J. Cherrington,et al.  Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments , 1998, Journal of Virology.

[72]  C. Crumpacker,et al.  Sequencing of Cytomegalovirus UL97 Gene for Genotypic Antiviral Resistance Testing , 2001, Antimicrobial Agents and Chemotherapy.

[73]  S. Chou,et al.  Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy. , 1998, The Journal of infectious diseases.

[74]  S. Tan,et al.  Cytomegalovirus (CMV) resistance in patients with CMV retinitis and AIDS treated with oral or intravenous ganciclovir. , 1999, The Journal of infectious diseases.

[75]  R. Sarisky,et al.  Characterization of Herpes Simplex Viruses Selected in Culture for Resistance to Penciclovir or Acyclovir , 2001, Journal of Virology.

[76]  M. Sawyer,et al.  Molecular analysis of the pyrimidine deoxyribonucleoside kinase gene of wild-type and acyclovir-resistant strains of varicella-zoster virus. , 1988, The Journal of general virology.

[77]  G. Faye,et al.  The 3′ to 5′ exonuclease activity located in the DNA polymerase delta subunit of Saccharomyces cerevisiae is required for accurate replication. , 1991, The EMBO journal.

[78]  M. Boeckh,et al.  Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. , 2001, Blood.

[79]  S. Chou,et al.  Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. , 1997, The Journal of infectious diseases.

[80]  M. Black,et al.  Purification and Photoaffinity Labeling of Herpes Simplex Virus Type-1 Thymidine Kinase (*) , 1995, The Journal of Biological Chemistry.

[81]  H. Balfour,et al.  Acyclovir susceptibilities of herpes simplex virus strains isolated from solid organ transplant recipients after acyclovir or ganciclovir prophylaxis , 1993, Antimicrobial Agents and Chemotherapy.

[82]  J. Duan,et al.  Antiviral Activity of a Selective Ribonucleotide Reductase Inhibitor against Acyclovir-Resistant Herpes Simplex Virus Type 1 In Vivo , 1998, Antimicrobial Agents and Chemotherapy.

[83]  P. Earl,et al.  Homology between DNA polymerases of poxviruses, herpesviruses, and adenoviruses: nucleotide sequence of the vaccinia virus DNA polymerase gene. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[84]  F. Baldanti,et al.  Mutations conferring ganciclovir resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. , 2001, The Journal of infectious diseases.

[85]  H. Balfour,et al.  Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients. , 1998, The Journal of infectious diseases.

[86]  D. Michel,et al.  Aciclovir selects for ganciclovir‐cross‐resistance of human cytomegalovirus in vitro that is only in part explained by known mutations in the UL97 protein * , 2001, Journal of medical virology.

[87]  M. Hunkapiller,et al.  Human DNA polymerase alpha gene expression is cell proliferation dependent and its primary structure is similar to both prokaryotic and eukaryotic replicative DNA polymerases. , 1988, The EMBO journal.

[88]  C. Crumpacker,et al.  Analysis of the thymidine kinase gene from clinically isolated acyclovir-resistant herpes simplex viruses. , 1991, Virology.

[89]  B. Larder,et al.  Characterization of a DNA polymerase mutant of herpes simplex virus from a severely immunocompromised patient receiving acyclovir. , 1989, The Journal of general virology.

[90]  B. Larder,et al.  Related functional domains in virus DNA polymerases. , 1987, The EMBO journal.

[91]  S. Clissold,et al.  Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. , 1991, Drugs.

[92]  H. Agut,et al.  Clinical and virologic characterization of acyclovir-resistant varicella-zoster viruses isolated from 11 patients with acquired immunodeficiency syndrome. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[93]  S. Spector,et al.  Molecular detection of human cytomegalovirus and determination of genotypic ganciclovir resistance in clinical specimens. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[94]  C. Mclaren,et al.  A colorimetric assay for the measurement of the sensitivity of herpes simplex viruses to antiviral agents. , 1983, Antiviral research.

[95]  D. Coen,et al.  Engineered herpes simplex virus DNA polymerase point mutants: the most highly conserved region shared among alpha-like DNA polymerases is involved in substrate recognition , 1990, Journal of virology.

[96]  C. Crumpacker,et al.  A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. , 1991, The New England journal of medicine.

[97]  D. Coen,et al.  A Recombinant Human Cytomegalovirus with a Large Deletion in UL97 Has a Severe Replication Deficiency , 1999, Journal of Virology.

[98]  D. Michel,et al.  GCV resistance due to the mutation A594P in the cytomegalovirus protein UL97 is partially reconstituted by a second mutation at D605E. , 2002, Antiviral research.

[99]  M. Aymard,et al.  Genetic characterization of thymidine kinase from acyclovir-resistant and -susceptible herpes simplex virus type 1 isolated from bone marrow transplant recipients. , 2000, The Journal of infectious diseases.

[100]  J. Cherrington,et al.  In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: relationship to clinical outcome. , 1998, The Journal of infectious diseases.

[101]  E. Swierkosz,et al.  Improved DNA hybridization method for detection of acyclovir-resistant herpes simplex virus , 1987, Antimicrobial Agents and Chemotherapy.

[102]  A. Hartmann,et al.  Flow cytometric analysis of herpes simplex virus type 1 susceptibility to acyclovir, ganciclovir, and foscarnet , 1997, Antimicrobial Agents and Chemotherapy.

[103]  M. Aymard,et al.  Reactivation of acyclovir‐resistant thymidine kinase‐deficient herpes simplex virus harbouring single base insertion within a 7 Gs homopolymer repeat of the thymidine kinase gene , 2000, Journal of medical virology.

[104]  B. Larder,et al.  Evidence that the 'active centre' of the herpes simplex virus thymidine kinase involves an interaction between three distinct regions of the polypeptide. , 1986, The Journal of general virology.

[105]  W. Freeman,et al.  Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma. , 1995, The Journal of clinical investigation.

[106]  K. Hayashi,et al.  BIOCHEMICAL STUDIES ON RICIN. I. PURIFICATION OF RICIN. , 1964, Journal of biochemistry.

[107]  F. Baldanti,et al.  The Cys607→Tyr Change in the UL97 Phosphotransferase Confers Ganciclovir Resistance to Two Human Cytomegalovirus Strains Recovered from Two Immunocompromised Patients , 1998, Antimicrobial Agents and Chemotherapy.

[108]  H. Balfour,et al.  Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. , 1989, The New England journal of medicine.

[109]  R. Esnouf,et al.  Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene. , 2000, The Journal of general virology.

[110]  S. Mori,et al.  Comparison of human cytomegalovirus DNA polymerase activity for ganciclovir-resistant and -sensitive clinical strains. , 2000, Antiviral research.

[111]  D. Coen,et al.  A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives , 1993, Antimicrobial Agents and Chemotherapy.

[112]  T. Klingebiel,et al.  Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. , 2000, Blood.

[113]  J. Subak-Sharpe,et al.  Biochemical studies on the herpes simplex virus-specified deoxypyrimidine kinase activity. , 1974, The Journal of general virology.

[114]  D. Coen,et al.  Effects of mutations in the Exo III motif of the herpes simplex virus DNA polymerase gene on enzyme activities, viral replication, and replication fidelity , 1997, Journal of virology.

[115]  E. Trulock,et al.  The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. , 1999, Transplantation.

[116]  M. Aymard,et al.  Occurrence and characterization of acyclovir‐resistant herpes simplex virus isolates: Report on a two—year sensitivity screening survey , 1992, Journal of medical virology.

[117]  J. Huraux,et al.  Foscarnet-resistant multidermatomal zoster in a patient with AIDS. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[118]  W. Owen,et al.  Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. , 1991, The Journal of infectious diseases.

[119]  W. Phelps,et al.  Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS , 1993, Journal of virology.

[120]  K. Struhl,et al.  DNA‐Dependent DNA Polymerases , 1997, Current protocols in molecular biology.

[121]  B. Terry,et al.  The structure and function of the HSV DNA replication proteins: defining novel antiviral targets. , 1993, Antiviral research.

[122]  H. Balfour Drug therapy : Antiviral drugs , 1999 .

[123]  F. Baldanti,et al.  Ganciclovir resistance as a result of oral ganciclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood. , 1998, Transplantation.

[124]  S. Fullerton,et al.  Pathophysiology and treatment of clinically resistant cytomegalovirus retinitis. , 1993, Ophthalmology.

[125]  H. Balfour,et al.  Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis. , 1998, The Journal of infectious diseases.

[126]  J. Sasadeusz,et al.  Spontaneous reactivation of thymidine kinase-deficient, acyclovir-resistant type-2 herpes simplex virus: masked heterogeneity or reversion? , 1996, The Journal of infectious diseases.

[127]  K. Knopf Properties of herpes simplex virus DNA polymerase and characterization of its associated exonuclease activity. , 1979, European journal of biochemistry.

[128]  C. B. Hwang,et al.  Mutations in the Exo III motif of the herpes simplex virus DNA polymerase gene can confer altered drug sensitivities. , 1998, Virology.

[129]  M. Saijo,et al.  Nucleotide sequence of thymidine kinase gene of sequential acyclovir‐resistant herpes simplex virus type 1 isolates recovered from a child with Wiskott–Aldrich syndrome: Evidence for reactivation of acyclovir‐resistant herpes simplex virus , 1999, Journal of medical virology.

[130]  M. Pettinger,et al.  Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients , 1993, Antimicrobial Agents and Chemotherapy.

[131]  S. Chou,et al.  Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. , 1995, The Journal of infectious diseases.

[132]  G. Gerna,et al.  A point mutation in the thymidine kinase gene is responsible for acyclovir-resistance in herpes simplex virus type 2 sequential isolates. , 1992, Virus research.

[133]  A. Limaye,et al.  Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants , 2000, The Lancet.

[134]  N. Lurain,et al.  Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir , 1994, Journal of virology.

[135]  J. C. Martin,et al.  Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. , 1992, Molecular pharmacology.

[136]  M. Tigges,et al.  Brief report: recurrent acyclovir-resistant genital herpes in an immunocompetent patient. , 1993, The New England journal of medicine.

[137]  C. Knopf The herpes simplex virus type 1 DNA polymerase gene: site of phosphonoacetic acid resistance mutation in strain Angelotti is highly conserved. , 1987, The Journal of general virology.

[138]  H. Balfour,et al.  Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. , 1994, The Journal of infectious diseases.

[139]  G. Hunter,et al.  In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus , 1991, Antimicrobial Agents and Chemotherapy.

[140]  S. Chou,et al.  Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. , 2002, The Journal of infectious diseases.

[141]  G. Darby,et al.  Survey of Resistance of Herpes Simplex Virus to Acyclovir in Northwest England , 1998, Antimicrobial Agents and Chemotherapy.

[142]  N. Lurain,et al.  Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents , 1992, Journal of virology.

[143]  H. Esperou,et al.  Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[144]  Y. Isashiki,et al.  Genetic analysis of a clinical isolate of human cytomegalovirus exhibiting resistance against both ganciclovir and cidofovir , 1997, Archives of Virology.

[145]  I. Sia,et al.  Novel mutation in the CMV UL97 gene associated with resistance to ganciclovir therapy. , 1999, Transplantation.

[146]  A. Davison,et al.  A cosmid-based system for constructing mutants of herpes simplex virus type 1. , 1993, Virology.

[147]  H. Shiota,et al.  Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: Analysis of clinical isolates from herpetic keratitis patients and laboratory strains , 1998, Journal of medical virology.

[148]  W. Freeman,et al.  Polyradiculopathy associated with ganciclovir-resistant cytomegalovirus in an AIDS patient: phenotypic and genotypic characterization of sequential virus isolates. , 1996, The Journal of infectious diseases.

[149]  D. Jabs,et al.  Incidence of Foscarnet Resistance and Cidofovir Resistance in Patients Treated for Cytomegalovirus Retinitis , 1998, Antimicrobial Agents and Chemotherapy.

[150]  D. Wolf,et al.  Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[151]  R. Whitley,et al.  Acyclovir: a decade later. , 1992, The New England journal of medicine.

[152]  C. Crumpacker,et al.  Characterization of an acyclovir-resistant herpes simplex virus type 2 strain isolated from a premature neonate. , 2000, The Journal of infectious diseases.

[153]  Vincent C. Emery,et al.  The Dynamics of Human Cytomegalovirus Replication in Vivo , 1999, The Journal of experimental medicine.

[154]  H. Kowarzyk Structure and Function. , 1910, Nature.

[155]  S. Chou,et al.  Novel mutation in the UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovir , 1995, Antimicrobial agents and chemotherapy.

[156]  D. Nelson,et al.  Metabolic activation of the nucleoside analog 9-[( 2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[157]  P. Meylan,et al.  A Rapid Phenotypic Assay for Detection of Acyclovir-Resistant Varicella-Zoster Virus with Mutations in the Thymidine Kinase Open Reading Frame , 2000, Antimicrobial Agents and Chemotherapy.

[158]  G. Boivin,et al.  Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy , 2002, Journal of medical virology.

[159]  H. Balfour,et al.  Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis. , 1993, The Journal of infectious diseases.

[160]  D. Pillay,et al.  Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance. , 2000, The Journal of infectious diseases.

[161]  R. Sudlow,et al.  Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. , 2001, The Journal of infectious diseases.

[162]  G. Gentry,et al.  Herpesviral deoxythymidine kinases contain a site analogous to the phosphoryl-binding arginine-rich region of porcine adenylate kinase; comparison of secondary structure predictions and conservation. , 1990, The Journal of general virology.

[163]  J. Rabkin,et al.  Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation. , 1997, Transplantation.

[164]  D. Coen,et al.  Penciclovir-Resistance Mutations in the Herpes Simplex Virus DNA Polymerase Gene , 1995 .

[165]  N. Flournoy,et al.  Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial. , 1982, Annals of internal medicine.

[166]  G. Boivin,et al.  Lack of Emergence of Cytomegalovirus UL97 Mutations Conferring Ganciclovir (GCV) Resistance following Preemptive GCV Therapy in Allogeneic Stem Cell Transplant Recipients , 2001, Antimicrobial Agents and Chemotherapy.

[167]  K. Schubert,et al.  Homopolymer mutational hot spots mediate herpes simplex virus resistance to acyclovir , 1997, Journal of virology.

[168]  C. Crumpacker,et al.  Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. , 1989, The New England journal of medicine.

[169]  H. Balfour,et al.  Herpes Simplex Virus Resistant to Acyclovir: A Study in a Tertiary Care Center , 1990 .

[170]  S. Chou,et al.  A Nine-Codon Deletion Mutation in the Cytomegalovirus UL97 Phosphotransferase Gene Confers Resistance to Ganciclovir , 2000, Antimicrobial Agents and Chemotherapy.

[171]  N. P. Pramod,et al.  Acyclovir Resistance in Herpes Simplex Virus Isolates from Keratitis Cases: An Analysis from a Developing Country , 2000, Microbiology and immunology.

[172]  A. Erice Resistance of Human Cytomegalovirus to Antiviral Drugs , 1999, Clinical Microbiology Reviews.

[173]  M. Garneau,et al.  A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo , 1994, Nature.

[174]  D. Coen,et al.  A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells , 1992, Nature.

[175]  S. Seo,et al.  Cytomegalovirus ventriculoencephalitis in a bone marrow transplant recipient receiving antiviral maintenance: clinical and molecular evidence of drug resistance. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[176]  Albert Balows,et al.  Manual of Clinical Microbiology, 7th ed. , 2000 .

[177]  N. Lurain,et al.  A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors. , 1992, The Journal of infectious diseases.

[178]  F. Baldanti,et al.  Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS , 1996, Journal of virology.

[179]  D. Jabs,et al.  Cytomegalovirus Retinitis and Viral Resistance: Ganciclovir Resistance , 1998 .

[180]  D. Coen,et al.  Pathogenicity of herpes simplex virus mutants containing drug resistance mutations in the viral DNA polymerase gene , 1986, Journal of virology.

[181]  S. Chou,et al.  Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. , 1995, The Journal of infectious diseases.

[182]  W. Drobyski,et al.  FOSCARNET THERAPY OF GANCICLOVIR‐RESISTANT CYTOMEGALOVIRUS IN MARROW TRANSPLANTATION , 1991, Transplantation.

[183]  D. Coen,et al.  A human cytomegalovirus mutant resistant to the nucleoside analog 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine (BW B759U) induces reduced levels of BW B759U triphosphate. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[184]  K. Tyler,et al.  Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[185]  M. Bergeron,et al.  Emergence and prevalence of cytomegalovirus UL97 mutations associated with ganciclovir resistance in AIDS patients , 1998, AIDS.

[186]  K. Tyler,et al.  A herpes simplex virus DNA polymerase mutation that specifically attenuates neurovirulence in mice. , 1998, Virology.

[187]  T. Berger,et al.  Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. , 1991, Annals of internal medicine.

[188]  D. Coen,et al.  A point mutation within a distinct conserved region of the herpes simplex virus DNA polymerase gene confers drug resistance , 1992, Journal of virology.

[189]  S. Spector,et al.  Detection of human cytomegalovirus mutations associated with ganciclovir resistance in cerebrospinal fluid of AIDS patients with central nervous system disease , 1995, Antimicrobial agents and chemotherapy.

[190]  M. Haffey,et al.  In vitro mutagenesis of the herpes simplex virus type 1 DNA polymerase gene results in altered drug sensitivity of the enzyme , 1989, Journal of virology.

[191]  C. Crumpacker,et al.  A Standardized Plaque Reduction Assay for Determination of Drug Susceptibilities of Cytomegalovirus Clinical Isolates , 2000, Antimicrobial Agents and Chemotherapy.

[192]  C. Crumpacker,et al.  Mechanism of action of foscarnet against viral polymerases. , 1992, The American journal of medicine.